Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2021-06-24

Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth

2021-06-24

INNODIA is ready for a new phase – clinical trials

2021-02-17

Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round – Pfizer Joins as Newest Shareholder

2021-02-03

Imcyse Enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis

2021-02-03

Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes

Go Back